Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 244

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 244
---
 110,675,600 ordinary shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series D warrants, or Series
D Warrants, at an exercise price of $400.00 per warrant and, (3) 4,426,800 ordinary shares represented by 442 Depositary Shares issuable
upon the exercise of warrants issued to the placement agent in the offering at an exercise price of $375.00 per warrant.

On June 20, 2023, we issued
the Series C Warrants, Series D Warrants and warrants issued to the placement agent after receiving required shareholder approval of the
allotment of, and disapplication of pre-emption rights with respect to the ordinary shares to be issued under the warrants at our June
GM.

Between June 20, 2023, and
December 31, 2024, we have issued 166,017,700 ordinary shares upon the exercise of Series C Warrants issued in the May 2023 registered
direct offering.

On July 5, 2023, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio of ordinary shares to Depositary Shares was changed such that one
Depositary Share represented 400 ordinary shares. Our ordinary shares were not affected by this change and no fractional Depositary Shares
were issued.

On November 22, 2023, we entered
into a series of agreements with (1) Adhera and certain of its secured noteholders, or the Secured Noteholders, and (1) Melior. On
December 21, 2023, in connection with the closing under the agreements, we issued (A) an aggregate of (i) 8,997 Depositary Shares to certain
of the Secured Noteholders and (ii) 90,999 pre-funded warrants to purchase Depositary Shares to certain of the Secured Noteholders, or
the December 2023 Private Placement Pre-Funded Warrants, and (B) 14,177 Depositary Shares to Melior. Between December 21, 2023 and December
31, 2024, we have issued 738,002,400 ordinary shares upon the exercise of December 2024 Private Placement Pre-Funded Warrants issued to
the Secured Noteholders.

On December 21, 2023, we completed
the closing of an underwritten public offering, pursuant to which we issued and sold (i) 43